Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne

Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) today announces initiation of the Phase III clinical trial of fatty acid synthase (FASN) inhibitor ASC40 (Denifanstat) for treatment of moderate to severe acne vulgaris. This Phase III clinical trial is a randomized, double-blind,…